Do analysts prefer BON or ARTL?

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Bon Natural Life. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bon Natural Life 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has higher earnings and valuation, BON or ARTL?

Bon Natural Life has higher revenue and earnings than Artelo Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bon Natural Life $18.67M 0.46 -$2M N/A N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is BON or ARTL more profitable?

Bon Natural Life's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Bon Natural Life N/A N/A N/A Artelo Biosciences N/A -1,600.12% -224.62%

Is ARTL or BCDA more profitable?

Artelo Biosciences' return on equity of -1,600.12% beat BioCardia's return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% BioCardia N/A -5,456.14% -232.75%

Do analysts recommend ASBP or ARTL?

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Artelo Biosciences is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Is ASBP or ARTL more profitable?

Aspire Biopharma's return on equity of 0.00% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Aspire Biopharma N/A N/A -398.04% Artelo Biosciences N/A -1,600.12% -224.62%

Do analysts recommend ARTL or SYBX?

Artelo Biosciences presently has a consensus price target of $54.00, suggesting a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Artelo Biosciences is more favorable than Synlogic. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 Synlogic 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ARTL or SYBX more profitable?

Synlogic's return on equity of -26.47% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Artelo Biosciences N/A -1,600.12% -224.62% Synlogic N/A -26.47% -18.00%

Do analysts rate OBSV or ARTL?

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Artelo Biosciences 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation & earnings, OBSV or ARTL?

Artelo Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Artelo Biosciences N/A N/A -$12.88M -$32.74 N/A

Is OBSV or ARTL more profitable?

ObsEva's return on equity of -416.36% beat Artelo Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Artelo Biosciences N/A -1,600.12% -224.62%

Artelo Biosciences (ARTL) Competitors

$0.75 -0.01 (-1.80%)

Closing price 04:00 PM Eastern

Extended Trading

$0.77 +0.02 (+2.62%)

As of 05:14 PM Eastern

Compare

ARTL vs. BON, BCDA, ASBP, SYBX, and OBSV

Should you buy Artelo Biosciences stock or one of its competitors? MarketBeat compares Artelo Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Artelo Biosciences include Bon Natural Life (BON), BioCardia (BCDA), Aspire Biopharma (ASBP), Synlogic (SYBX), and ObsEva (OBSV).

How does Artelo Biosciences compare to Bon Natural Life?

Bon Natural Life (NASDAQ:BON) and Artelo Biosciences (NASDAQ:ARTL) are related small-cap companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, institutional ownership, earnings, analyst recommendations, valuation and dividends.

Bon Natural Life has a beta of -0.28, meaning that its stock price is 128% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market.

In the previous week, Bon Natural Life had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Bon Natural Life and 0 mentions for Artelo Biosciences. Bon Natural Life's average media sentiment score of 1.32 beat Artelo Biosciences' score of 0.00 indicating that Bon Natural Life is being referred to more favorably in the media.

Company	Overall Sentiment
Bon Natural Life	Positive
Artelo Biosciences	Neutral

Artelo Biosciences has a consensus price target of $54.00, indicating a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than Bon Natural Life.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bon Natural Life	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Bon Natural Life has higher revenue and earnings than Artelo Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bon Natural Life	$18.67M	0.46	-$2M	N/A	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Bon Natural Life's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bon Natural Life	N/A	N/A	N/A
Artelo Biosciences	N/A	-1,600.12%	-224.62%

0.6% of Bon Natural Life shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 26.5% of Bon Natural Life shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Bon Natural Life beats Artelo Biosciences on 7 of the 11 factors compared between the two stocks.

How does Artelo Biosciences compare to BioCardia?

Artelo Biosciences (NASDAQ:ARTL) and BioCardia (NASDAQ:BCDA) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

0.9% of Artelo Biosciences shares are owned by institutional investors. Comparatively, 20.6% of BioCardia shares are owned by institutional investors. 3.2% of Artelo Biosciences shares are owned by company insiders. Comparatively, 17.4% of BioCardia shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Artelo Biosciences' return on equity of -1,600.12% beat BioCardia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
BioCardia	N/A	-5,456.14%	-232.75%

Artelo Biosciences currently has a consensus target price of $54.00, indicating a potential upside of 7,087.54%. BioCardia has a consensus target price of $25.00, indicating a potential upside of 2,531.58%. Given Artelo Biosciences' higher possible upside, analysts plainly believe Artelo Biosciences is more favorable than BioCardia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
BioCardia	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

BioCardia has higher revenue and earnings than Artelo Biosciences. BioCardia is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
BioCardia	$60K	180.18	-$8.23M	-$0.91	N/A

Artelo Biosciences has a beta of -0.07, meaning that its stock price is 107% less volatile than the broader market. Comparatively, BioCardia has a beta of 0.48, meaning that its stock price is 52% less volatile than the broader market.

In the previous week, BioCardia had 3 more articles in the media than Artelo Biosciences. MarketBeat recorded 3 mentions for BioCardia and 0 mentions for Artelo Biosciences. Artelo Biosciences' average media sentiment score of 0.00 equaled BioCardia'saverage media sentiment score.

Company	Overall Sentiment
Artelo Biosciences	Neutral
BioCardia	Neutral

Summary

BioCardia beats Artelo Biosciences on 8 of the 12 factors compared between the two stocks.

How does Artelo Biosciences compare to Aspire Biopharma?

Aspire Biopharma (NASDAQ:ASBP) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, earnings and dividends.

In the previous week, Aspire Biopharma had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Aspire Biopharma and 0 mentions for Artelo Biosciences. Aspire Biopharma's average media sentiment score of 0.56 beat Artelo Biosciences' score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Aspire Biopharma	Positive
Artelo Biosciences	Neutral

Artelo Biosciences has a consensus target price of $54.00, suggesting a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Artelo Biosciences is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Aspire Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, indicating that its share price is 107% less volatile than the broader market.

19.2% of Aspire Biopharma shares are held by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are held by institutional investors. 5.8% of Aspire Biopharma shares are held by company insiders. Comparatively, 3.2% of Artelo Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Aspire Biopharma's return on equity of 0.00% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aspire Biopharma	N/A	N/A	-398.04%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Artelo Biosciences has lower revenue, but higher earnings than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aspire Biopharma	$10K	950.95	-$24.48M	-$116.67	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

Summary

Aspire Biopharma beats Artelo Biosciences on 7 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to Synlogic?

Artelo Biosciences (NASDAQ:ARTL) and Synlogic (NASDAQ:SYBX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership.

0.9% of Artelo Biosciences shares are held by institutional investors. Comparatively, 63.4% of Synlogic shares are held by institutional investors. 3.2% of Artelo Biosciences shares are held by company insiders. Comparatively, 2.6% of Synlogic shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Artelo Biosciences has higher earnings, but lower revenue than Synlogic. Synlogic is trading at a lower price-to-earnings ratio than Artelo Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A
Synlogic	$8K	1,806.73	-$23.36M	-$0.06	N/A

In the previous week, Synlogic had 1 more articles in the media than Artelo Biosciences. MarketBeat recorded 1 mentions for Synlogic and 0 mentions for Artelo Biosciences. Synlogic's average media sentiment score of 0.49 beat Artelo Biosciences' score of 0.00 indicating that Synlogic is being referred to more favorably in the news media.

Company	Overall Sentiment
Artelo Biosciences	Neutral
Synlogic	Neutral

Synlogic's return on equity of -26.47% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Artelo Biosciences	N/A	-1,600.12%	-224.62%
Synlogic	N/A	-26.47%	-18.00%

Artelo Biosciences presently has a consensus price target of $54.00, suggesting a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher possible upside, equities analysts plainly believe Artelo Biosciences is more favorable than Synlogic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
Synlogic	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Artelo Biosciences has a beta of -0.07, meaning that its share price is 107% less volatile than the broader market. Comparatively, Synlogic has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Summary

Synlogic beats Artelo Biosciences on 8 of the 13 factors compared between the two stocks.

How does Artelo Biosciences compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Artelo Biosciences (NASDAQ:ARTL) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 0.9% of Artelo Biosciences shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 3.2% of Artelo Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Artelo Biosciences has a consensus target price of $54.00, indicating a potential upside of 7,087.54%. Given Artelo Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Artelo Biosciences is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Artelo Biosciences	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

ObsEva has a beta of 0.68, suggesting that its share price is 32% less volatile than the broader market. Comparatively, Artelo Biosciences has a beta of -0.07, suggesting that its share price is 107% less volatile than the broader market.

In the previous week, ObsEva's average media sentiment score of 0.00 equaled Artelo Biosciences'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Artelo Biosciences	Neutral

Artelo Biosciences is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Artelo Biosciences	N/A	N/A	-$12.88M	-$32.74	N/A

ObsEva's return on equity of -416.36% beat Artelo Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Artelo Biosciences	N/A	-1,600.12%	-224.62%

Summary

ObsEva beats Artelo Biosciences on 7 of the 10 factors compared between the two stocks.

Get Artelo Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARTL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARTL vs. The Competition

Export

Metric	Artelo Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.75M	$11.67B	$6.90B	$12.86B
Dividend Yield	N/A	2.73%	2.60%	10.00%
P/E Ratio	-0.02	791.56	280.82	25.41
Price / Sales	N/A	740.97	599.65	90.75
Price / Cash	N/A	71.54	72.11	49.40
Price / Book	-0.40	10.85	12.95	6.08
Net Income	-$12.88M	$2.82B	$3.49B	$348.07M
7 Day Performance	3.86%	3.46%	3.60%	4.72%
1 Month Performance	-32.32%	-1.92%	-2.51%	-2.12%
1 Year Performance	-97.36%	193.09%	73.85%	20.56%

Artelo Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARTL Artelo Biosciences	1.641 of 5 stars	$0.75 -1.8%	$54.00 +7,087.5%	-97.4%	$1.75M	N/A	N/A	5	Upcoming Earnings
BON Bon Natural Life	0.8956 of 5 stars	$1.14 +0.2%	N/A	-17.3%	$9.25M	$18.67M	N/A	100	Positive News
BCDA BioCardia	2.7645 of 5 stars	$0.78 -3.3%	$25.00 +3,099.0%	-53.6%	$9.19M	$60K	N/A	40	News Coverage Upcoming Earnings Gap Up
ASBP Aspire Biopharma	0.18 of 5 stars	$7.24 +3.9%	N/A	-98.4%	$9.03M	$10K	N/A	N/A	News Coverage Positive News
SYBX Synlogic	0.2044 of 5 stars	$0.72 +7.5%	N/A	-21.3%	$8.42M	$8K	N/A	80

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARTL) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Artelo Biosciences (ARTL) Competitors

ARTL vs. BON, BCDA, ASBP, SYBX, and OBSV

How does Artelo Biosciences compare to Bon Natural Life?

Summary

How does Artelo Biosciences compare to BioCardia?

Summary

How does Artelo Biosciences compare to Aspire Biopharma?

Summary

How does Artelo Biosciences compare to Synlogic?

Summary

How does Artelo Biosciences compare to ObsEva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Artelo Biosciences (ARTL) Competitors

ARTL vs. BON, BCDA, ASBP, SYBX, and OBSV

How does Artelo Biosciences compare to Bon Natural Life?

Which has more volatility and risk, BON or ARTL?

Does the media prefer BON or ARTL?

Do analysts prefer BON or ARTL?

Which has higher earnings and valuation, BON or ARTL?

Is BON or ARTL more profitable?

Do insiders & institutionals believe in BON or ARTL?

Summary

How does Artelo Biosciences compare to BioCardia?

Do institutionals and insiders believe in ARTL or BCDA?

Is ARTL or BCDA more profitable?

Do analysts recommend ARTL or BCDA?

Which has stronger earnings and valuation, ARTL or BCDA?

Which has more risk and volatility, ARTL or BCDA?

Does the media favor ARTL or BCDA?

Summary

How does Artelo Biosciences compare to Aspire Biopharma?

Does the media prefer ASBP or ARTL?

Do analysts recommend ASBP or ARTL?

Which has more volatility and risk, ASBP or ARTL?

Do institutionals & insiders have more ownership in ASBP or ARTL?

Is ASBP or ARTL more profitable?

Which has preferable earnings & valuation, ASBP or ARTL?

Summary

How does Artelo Biosciences compare to Synlogic?

Do insiders & institutionals hold more shares of ARTL or SYBX?

Which has higher valuation & earnings, ARTL or SYBX?

Does the media refer more to ARTL or SYBX?

Is ARTL or SYBX more profitable?

Do analysts recommend ARTL or SYBX?

Which has more risk & volatility, ARTL or SYBX?

Summary

How does Artelo Biosciences compare to ObsEva?

Do institutionals and insiders hold more shares of OBSV or ARTL?

Do analysts rate OBSV or ARTL?

Which has more volatility and risk, OBSV or ARTL?

Does the media refer more to OBSV or ARTL?

Which has stronger valuation & earnings, OBSV or ARTL?

Is OBSV or ARTL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARTL vs. The Competition

Artelo Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools